Ultragenyx Pharmaceutical financials
$15.32+6.32%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 | FY20 Dec 31 | FY19 Dec 31 | FY18 Dec 31 | FY17 Dec 31 | FY16 Dec 31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $673.0M | $560.0M | $434.0M | $363.3M | $351.4M | $271.0M | $103.7M | $51.5M | $2.6M | $133.0K |
| Gross profit | $564.0M | $483.0M | $389.0M | $335.0M | $335.4M | $264.9M | $94.7M | $50.3M | $2.6M | $133.0K |
| Gross margin | 83.8% | 86.3% | 89.6% | 92.2% | 95.4% | 97.7% | 91.3% | 97.8% | 100.0% | 100.0% |
| Operating income | -$535.0M | -$536.0M | -$569.0M | -$648.9M | -$381.7M | -$330.1M | -$424.2M | -$371.4M | -$328.9M | -$248.0M |
| Net income | -$575.0M | -$569.0M | -$607.0M | -$707.4M | -$454.0M | -$186.6M | -$402.7M | -$197.6M | -$302.1M | -$245.9M |
| Net margin | −85.4% | −101.6% | −139.9% | −194.7% | −129.2% | −68.8% | −388.3% | −383.7% | −11567.3% | −184867.7% |
| Diluted EPS | $-5.83 | $-6.29 | $-8.25 | $-10.12 | $-6.70 | $-3.07 | $-7.12 | $-3.97 | $-7.12 | $-6.21 |
| EBITDA | -$500.0M | -$500.0M | -$543.0M | -$630.7M | -$368.5M | -$317.9M | -$415.6M | -$351.8M | -$323.1M | -$244.6M |
| Operating cash flow | -$466.0M | -$414.0M | -$475.0M | -$380.5M | -$338.7M | -$132.2M | -$345.4M | -$290.6M | -$253.8M | -$161.0M |
| Free cash flow | -$472.0M | -$421.0M | -$519.0M | -$496.6M | -$411.8M | -$176.1M | -$370.2M | -$294.6M | -$256.6M | -$171.2M |
| Diluted shares | 98.6M | 90.5M | 73.5M | 69.9M | 67.8M | 60.8M | 56.6M | 49.8M | 42.5M | 39.6M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $421.0M | $174.0M | $213.6M | $132.9M | $307.6M | $713.5M |
| Short-term investments | $259.0M | $436.0M | $363.6M | $614.8M | $432.6M | $488.0M |
| Total debt | $0.00 | $0.00 | $0.00 | $875.4M | $351.8M | $335.7M |
| Total assets | $1.53B | $1.50B | $1.49B | $1.55B | $1.52B | $1.76B |
| Total liabilities | $1.60B | $1.24B | $1.22B | $1.19B | $599.8M | $605.2M |
| Shareholders' equity | -$73.0M | $255.0M | $275.4M | $352.5M | $922.6M | $1.15B |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology